相关实验视频

Updated: Jun 27, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

综合性有氧运动与LDE-docetaxel治疗:对抗前列腺癌进展的新方法

Allice Santos Cruz Veras¹, Victor Rogério Garcia Batista¹, Rafael Ribeiro Correia¹

¹Multicenter Graduate Program in Physiological Sciences, SBFis, São Paulo State University (UNESP), Presidente Prudente, SP, Brazil.

Scientific reports

|April 26, 2024

概括

将脂质纳米乳液 (LDE) docetaxel (DTX) 与有氧运动相结合,可以改善前列腺癌的治疗. 这种方法减少了瘤生长,改善了细胞循环调节,并提供了代谢益处.

科学领域:

在瘤学瘤学.
纳米医学是一种纳米医学.
运动生理学运动生理学

背景情况:

前列腺癌 (PC) 治疗面临的挑战是由于治疗的可变性和耐药性.
有氧运动在预防癌症方面表现有前途,但机制尚不清楚.
需要新的药物输送系统来提高治疗疗效.

研究的目的:

为了研究一个脂质纳米乳液 (LDE) 输送系统的协同效应,为dcetaxel (DTX) 结合有氧体力炼在前列腺癌.
阐明这种联合干预的增强抗瘤活性背后的机制.

主要方法:

使用脂质纳米乳液 (LDE) 来提供多塞塔克塞尔 (DTX).
在临床前模型中,结合了LDE-DTX与结构化的有氧体力炼方案.
评估瘤生长,细胞循环进展,蛋白质表达 (BCL-2,亲细胞亡蛋白),炎症标志物和代谢概况.

主要成果:

联合疗法显著降低了前列腺体重和腺癌增殖.
观察到增强的纳米粒子内部化和诱导细胞循环停止.
发现了减弱的抗亡性BCL-2表达和高亡性蛋白质.
在联合治疗组中发现炎症标志物,脂质和血葡萄糖水平降低.

结论:

将LDE介导的DTX输送与有氧运动相结合,是对抗前列腺癌的强大多式策略.
这种协同方法通过改善药物递送和细胞周期调节来增强抗瘤活性.
组合疗法提供了显著的治疗效益,包括减少瘤负担和改善代谢参数,为新的PC管理范式铺平了道路.

关键词:

耐力体育训练是一种耐力体育训练.欧美国家和地区 LDE LDE 纳米乳液是一种纳米乳液.拉曼光谱法拉曼光谱法拉曼光谱法纳税人就是纳税人.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...